CloudAlpha Capital Management Limited Hong Kong Buys New Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Key Points

• CloudAlpha Capital Management Limited Hong Kong has acquired a total of 696,441 shares of Hims & Hers Health, valued at approximately $20.58 million, making it the 13th largest holding in its portfolio.
• Several hedge funds, including Vanguard Group and Farallon Capital Management, have significantly increased their stake in Hims & Hers Health during the fourth quarter, indicating strong institutional interest.
• Hims & Hers Health recently posted earnings, reporting a 110.7% increase in revenue year-over-year, alongside a positive earnings beat at $0.20 EPS compared to an expected $0.12 EPS.

CloudAlpha Capital Management Limited Hong Kong acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 696,441 shares of the company's stock, valued at approximately $20,580,000. Hims & Hers Health accounts for approximately 1.6% of CloudAlpha Capital Management Limited Hong Kong's holdings, making the stock its 13th largest holding. CloudAlpha Capital Management Limited Hong Kong owned about 0.31% of Hims & Hers Health at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. UMB Bank n.a. grew its stake in shares of Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after buying an additional 933 shares in the last quarter. Larson Financial Group LLC grew its stake in shares of Hims & Hers Health by 47.7% in the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock valued at $42,000 after buying an additional 458 shares in the last quarter. Tsfg LLC bought a new stake in shares of Hims & Hers Health in the 1st quarter valued at approximately $46,000. Fifth Third Bancorp grew its stake in shares of Hims & Hers Health by 165.4% in the 1st quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock valued at $46,000 after buying an additional 961 shares in the last quarter. Finally, Summit Securities Group LLC bought a new stake in shares of Hims & Hers Health in the 4th quarter valued at approximately $38,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Buying and Selling

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,581 shares of the company's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $47.70, for a total value of $552,413.70. Following the sale, the chief financial officer directly owned 54,084 shares in the company, valued at $2,579,806.80. This represents a 17.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Soleil Boughton sold 2,572 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $47.82, for a total value of $122,993.04. Following the sale, the insider owned 158,165 shares in the company, valued at $7,563,450.30. The trade was a 1.60% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 788,368 shares of company stock valued at $42,410,254. 13.71% of the stock is currently owned by insiders.

Hims & Hers Health Price Performance

Shares of NYSE HIMS traded up $0.18 during trading hours on Friday, reaching $57.50. The stock had a trading volume of 46,302,225 shares, compared to its average volume of 30,801,588. The business's fifty day moving average is $53.15 and its two-hundred day moving average is $42.77. The company has a market cap of $12.87 billion, a price-to-earnings ratio of 83.33, a PEG ratio of 2.11 and a beta of 2.02. Hims & Hers Health, Inc. has a twelve month low of $13.47 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. The business had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. Hims & Hers Health's revenue was up 110.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.05 earnings per share. Sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

HIMS has been the subject of several recent research reports. TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and lowered their price target for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Wall Street Zen raised Hims & Hers Health from a "hold" rating to a "buy" rating in a research note on Sunday, July 20th. Piper Sandler reaffirmed a "neutral" rating and set a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Finally, Morgan Stanley reaffirmed an "equal weight" rating and set a $40.00 target price on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $39.83.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.